About Us

Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology.  Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and  Versatis® brands.  To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries.  TPU recently also received NDA approval for Non-alcohol Docetaxel injection currently available in the US.

Latest News and Events

May 30, 2018

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China
SAN JOSE, Calif.,May 30, 2018--Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and distribute TPU’s flagship product, Lidoderm®, in China. Lidoderm® offers relief of the pain associated with post-herpetic neuralgia (“PHN”). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.

Read more | View All

Innovation

Teikoku is building a robust pipeline of drug candidates which may expand the reach and benefit of existing therapeutics.   

Learn more about our pipeline.

Products

Teikoku USA has two FDA and one EMEA approved products in the market.
Learn more about our approved products.

Development

We employ our Hydrohesive, Matrix and other drug delivery technologies to expand our product pipeline.
Learn More About Our Technologies.